Cytokinetics launches ASPEN-HCM real-world study for MYQORZO in obstructive hypertrophic cardiomyopathy

The prospective ASPEN-HCM study will track MYQORZO in adults with symptomatic obstructive hypertrophic cardiomyopathy, collecting outcomes over 12 to 36 months in routine clinical practice, with ~400 patients across 13 sites.